Australian Clinical Labs Ltd (ACL)
Australian Securities Exchange · Australia · prices in AUD · close of 23 Oct 2026
Key indicators
| Last close | AUD 2.930 |
|---|---|
| 52-week range | 1.833 – 3.030 |
| Return, 1 month / 3 months | +2.8% / +35.9% |
| Return, 1 year / 3 years | +12.1% / +19.6% |
| Trend | Uptrend |
| RSI (14) | 62 |
| Volatility (1 year) | 33.8% |
| Worst drawdown (1 year) | -36.0% |
| Average daily value traded | 1.80M AUD |
| Dividend yield | 4.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Australian Clinical Labs is a pathology company based in Melbourne that provides diagnostic testing services across Australia. It operates a network of laboratories and collection centres, offering blood tests, microbiology, anatomical pathology and other clinical testing for doctors, hospitals and patients. Its services support medical diagnosis and treatment decisions, and it also runs specialised testing for areas such as genetics and occupational health.
Australian Clinical Labs Ltd trades under the code ACL on the Australian Securities Exchange in Australia, with its price quoted in Australian dollars (AUD). Our dividend records, which start in 2019, show payments in 5 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Australian Clinical Labs Ltd (ACL) trades on the Australian Securities Exchange in Australia. It last closed at AUD 2.930 on 23 October 2026.
Its price-based Market X-Ray is 83 out of 100 (a strong price profile), ranking 45 of 1,816 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 12.1% and over the last three months it rose 35.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Australian Securities Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 96 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 27.7% | ||
| From 52-week high | -2.0% | ||
| Momentum | 89 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 35.9% | ||
| 6-month return | 54.6% | ||
| 12-month return, skipping the last month | 9.1% | ||
| Stability (higher is calmer) | 80 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 33.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -36.0% | ||
| Liquidity | 83 · Strong | Trades actively. | |
| Average daily value traded | 1.80M AUD | ||
| Zero-volume days | 0.0% | ||
| Income | 49 · Weak | Dividend is small or irregular. | |
| Dividend yield | 4.4% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +2.4% |
|---|---|
| 1 month | +2.8% |
| 3 months | +35.9% |
| 6 months | +54.6% |
| 1 year | +12.1% |
| 3 years | +19.6% |
| 5 years | −8.6% |
Signals
| 50-day / 200-day average | 2.810 / 2.294 |
|---|---|
| Golden / death cross (60 days) | Golden, 46 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.072 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 2 Sep 2026 | AUD 0.0925 |
| 12 Mar 2026 | AUD 0.0375 |
| 1 Sep 2025 | AUD 0.0900 |
| 27 Mar 2025 | AUD 0.0350 |
| 4 Sep 2024 | AUD 0.0900 |
| 28 Mar 2024 | AUD 0.0300 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Australian Securities Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.